Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Eric R Braverman

Biographic Data

ID899029
NAMEEric R Braverman
GIVEN NAMESEric R
FAMILY NAMEBraverman
SIGNATUREBRAVERMAN E R
AFFILIATIONSCornell University
ORCID0000-0001-5525-8314
VERIFIEDYes
TOTAL WORKS10
TOTAL CITATIONS0
AUTHOR COUNT10
EDITOR COUNT0
FIRST PUBLICATION YEAR2000
LATEST PUBLICATION YEAR2022
H-INDEX0
  • Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (Gars) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic…

    Open Access•Ashim Gupta, Abdalla Bowirrat et al.•ARTICLE•International Journal of…•2022

    In the United States, amid the opioid overdose epidemic, nonaddicting/nonpharmacological proven strategies are available to treat pain and manage chronic pain effectively without opioids. Evidence supporting the long-term use of opioids for pain is lacking, as is the will to alter the drug-embracing culture in American chronic pain management. Some pain clinicians seem to prefer classical analgesic agents that promote unwanted tolerance to analge…

  • Reward Deficiency Syndrome (RDS)

    Open Access•Kenneth Blum, Abdalla Bowirrat et al.•ARTICLE•International Journal of…•2021

    Alcohol and other substance use disorders share comorbidity with other RDS disorders, i.e., a reduction in dopamine signaling within the reward pathway. RDS is a term that connects addictive, obsessive, compulsive, and impulsive behavioral disorders. An estimated 2 million individuals in the United States have opioid use disorder related to prescription opioids. It is estimated that the overall cost of the illegal and legally prescribed opioid cr…

  • Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors

    Open Access•Kenneth Blum, Marjorie C Gondré-Lewis et al.•ARTICLE•Frontiers in Psychiatry•2018

    reward deficiency syndrome (RDS), dopamine homeostasis, genetic addiction risk score (GARS), comprehensive analysis of reported drugs (CARD), precision addiction management (PAM)

  • The Addictive Brain

    Kenneth Blum, Amanda LC Chen et al.•ARTICLE•Journal of Psychoactive Drugs•2012

    This article will touch on theories, scientific research and conjecture about the evolutionary genetics of the brain function and the impact of genetic variants called polymorphisms on drug-seeking behavior. It will cover the neurological basis of pleasure-seeking and addiction, which affects multitudes in a global atmosphere where people are seeking "pleasure states"

  • Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (Naat)TM Improves Behavioral Outcomes in a Residential Addiction Treatment Program

    Merlene Miller, Amanda LC Chen et al.•ARTICLE•Journal of Psychoactive Drugs•2012

    Substance use disorders (SUD) are inheritable and the culprit is hypodopaminergic function regulated by reward genes. We evaluated a natural dopaminergic agonist; KB220 intravenous (IV) and oral variants, to improve dopaminergic function in SUD. Our pilot experiment found a significant reduction of chronic symptoms, measured by the Chronic Abstinence Symptom Severity (CASS) Scale. The combined group (IV and oral) did significantly better than the…

  • Generational Association Studies of Dopaminergic Genes in Reward Deficiency Syndrome (RDS) Subjects

    Open Access•Kenneth Blum, Amanda LC Chen et al.•ARTICLE•International Journal of…•2011

    Although our sample size was limited, and linkage analysis is necessary, the results support the putative role of dopaminergic polymorphisms in RDS behaviors. This study shows the importance of a nonspecific RDS phenotype and informs an understanding of how evaluating single subset behaviors of RDS may lead to spurious results. Utilization of a nonspecific "reward" phenotype may be a paradigm shift in future association and linkage studies involv…

  • Neurogenetics and Clinical Evidence for the Putative Activation of the Brain Reward Circuitry by a Neuroadaptagen

    Thomas J H Chen, Kenneth Blum et al.•ARTICLE•Journal of Psychoactive Drugs•2011

    This document presents evidence supporting the role of the KB220/KB220Z neuroadaptagens consisting of amino-acid neurotransmitter precursors and enkephalinase-catecholamine-methyl-transferase (COMT) inhibition therapy called Neuroadaptagen Amino Acid Therapy (NAAT) in brain reward function. It is becoming increasingly clear that this novel formulation is the first neuroadaptagen known to activate the brain reward circuitry. Ongoing research repea…

  • Hypothesizing that Marijuana Smokers are at a Significantly Lower Risk of Carcinogenicity Relative to Tobacco-Non-Marijuana Smokers

    Amanda LC Chen, Amanda L C Chen et al.•ARTICLE•Journal of Psychoactive Drugs•2008

    A hypothetical link between marijuana smoking and cancer has been established based on a number of misleading assumptions. However, recent studies tend to suggest, if anything, an inverse association between marijuana use and cancers. To test the hypothesis that marijuana smoking significantly lowers the risk of developing cancer in humans, we analyzed published data from a prospective cohort study on cancer incidence among nonsmokers (NS), marij…

  • Nutrigenomics and pharmacogenomics

    Open Access•Kenneth Blum, Thomas J H Chen et al.•ARTICLE•Social Science Information•2006•References: 33

    English As scientists engaged in understanding the potential of drug/nutrient responses as a function of our genome and all of its ramifications including academic and commercial aspects, our future looks bright. While, however, being cautious about our future especially in terms of regulatory issues, gene-nutrition interactions especially related to genome-based response will indeed be the next cornerstone of solid scientific approaches to assis…

  • The Reward Deficiency Syndrome

    Kenneth Blum, Eric R Braverman et al.•ARTICLE•Journal of Psychoactive Drugs•2000

    The dopaminergic system, and in particular the dopamine D2 receptor, has been implicated in reward mechanisms. The net effect of neurotransmitter interaction at the mesolimbic brain region induces "reward" when dopamine (DA) is released from the neuron at the nucleus accumbens and interacts with a dopamine D2 receptor. "The reward cascade" involves the release of serotonin, which in turn at the hypothalmus stimulates enkephalin, which in turn inh…

No prominent works on this page.

  • The Reward Deficiency Syndrome

    Kenneth Blum, Eric R Braverman et al.•ARTICLE•Journal of Psychoactive Drugs•2000

    The dopaminergic system, and in particular the dopamine D2 receptor, has been implicated in reward mechanisms. The net effect of neurotransmitter interaction at the mesolimbic brain region induces "reward" when dopamine (DA) is released from the neuron at the nucleus accumbens and interacts with a dopamine D2 receptor. "The reward cascade" involves the release of serotonin, which in turn at the hypothalmus stimulates enkephalin, which in turn inh…

  • Nutrigenomics and pharmacogenomics

    Open Access•Kenneth Blum, Thomas J H Chen et al.•ARTICLE•Social Science Information•2006•References: 33

    English As scientists engaged in understanding the potential of drug/nutrient responses as a function of our genome and all of its ramifications including academic and commercial aspects, our future looks bright. While, however, being cautious about our future especially in terms of regulatory issues, gene-nutrition interactions especially related to genome-based response will indeed be the next cornerstone of solid scientific approaches to assis…

  • Hypothesizing that Marijuana Smokers are at a Significantly Lower Risk of Carcinogenicity Relative to Tobacco-Non-Marijuana Smokers

    Amanda LC Chen, Amanda L C Chen et al.•ARTICLE•Journal of Psychoactive Drugs•2008

    A hypothetical link between marijuana smoking and cancer has been established based on a number of misleading assumptions. However, recent studies tend to suggest, if anything, an inverse association between marijuana use and cancers. To test the hypothesis that marijuana smoking significantly lowers the risk of developing cancer in humans, we analyzed published data from a prospective cohort study on cancer incidence among nonsmokers (NS), marij…

  • Generational Association Studies of Dopaminergic Genes in Reward Deficiency Syndrome (RDS) Subjects

    Open Access•Kenneth Blum, Amanda LC Chen et al.•ARTICLE•International Journal of…•2011

    Although our sample size was limited, and linkage analysis is necessary, the results support the putative role of dopaminergic polymorphisms in RDS behaviors. This study shows the importance of a nonspecific RDS phenotype and informs an understanding of how evaluating single subset behaviors of RDS may lead to spurious results. Utilization of a nonspecific "reward" phenotype may be a paradigm shift in future association and linkage studies involv…

  • Neurogenetics and Clinical Evidence for the Putative Activation of the Brain Reward Circuitry by a Neuroadaptagen

    Thomas J H Chen, Kenneth Blum et al.•ARTICLE•Journal of Psychoactive Drugs•2011

    This document presents evidence supporting the role of the KB220/KB220Z neuroadaptagens consisting of amino-acid neurotransmitter precursors and enkephalinase-catecholamine-methyl-transferase (COMT) inhibition therapy called Neuroadaptagen Amino Acid Therapy (NAAT) in brain reward function. It is becoming increasingly clear that this novel formulation is the first neuroadaptagen known to activate the brain reward circuitry. Ongoing research repea…

  • The Addictive Brain

    Kenneth Blum, Amanda LC Chen et al.•ARTICLE•Journal of Psychoactive Drugs•2012

    This article will touch on theories, scientific research and conjecture about the evolutionary genetics of the brain function and the impact of genetic variants called polymorphisms on drug-seeking behavior. It will cover the neurological basis of pleasure-seeking and addiction, which affects multitudes in a global atmosphere where people are seeking "pleasure states"

  • Early Intervention of Intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (Naat)TM Improves Behavioral Outcomes in a Residential Addiction Treatment Program

    Merlene Miller, Amanda LC Chen et al.•ARTICLE•Journal of Psychoactive Drugs•2012

    Substance use disorders (SUD) are inheritable and the culprit is hypodopaminergic function regulated by reward genes. We evaluated a natural dopaminergic agonist; KB220 intravenous (IV) and oral variants, to improve dopaminergic function in SUD. Our pilot experiment found a significant reduction of chronic symptoms, measured by the Chronic Abstinence Symptom Severity (CASS) Scale. The combined group (IV and oral) did significantly better than the…

  • Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors

    Open Access•Kenneth Blum, Marjorie C Gondré-Lewis et al.•ARTICLE•Frontiers in Psychiatry•2018

    reward deficiency syndrome (RDS), dopamine homeostasis, genetic addiction risk score (GARS), comprehensive analysis of reported drugs (CARD), precision addiction management (PAM)

  • Reward Deficiency Syndrome (RDS)

    Open Access•Kenneth Blum, Abdalla Bowirrat et al.•ARTICLE•International Journal of…•2021

    Alcohol and other substance use disorders share comorbidity with other RDS disorders, i.e., a reduction in dopamine signaling within the reward pathway. RDS is a term that connects addictive, obsessive, compulsive, and impulsive behavioral disorders. An estimated 2 million individuals in the United States have opioid use disorder related to prescription opioids. It is estimated that the overall cost of the illegal and legally prescribed opioid cr…

  • Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (Gars) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic…

    Open Access•Ashim Gupta, Abdalla Bowirrat et al.•ARTICLE•International Journal of…•2022

    In the United States, amid the opioid overdose epidemic, nonaddicting/nonpharmacological proven strategies are available to treat pain and manage chronic pain effectively without opioids. Evidence supporting the long-term use of opioids for pain is lacking, as is the will to alter the drug-embracing culture in American chronic pain management. Some pain clinicians seem to prefer classical analgesic agents that promote unwanted tolerance to analge…

Addiction (8 works) · Medicine (8 works) · Attention Deficit Hyperactivity Disorder (7 works) · Dopamine (7 works) · Neurotransmitter Receptor Influence on Behavior (7 works) · Psychiatry (7 works) · Psychology (7 works) · Dopaminergic (6 works) · Internal Medicine (4 works) · Neuroscience (4 works)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae